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Transcription factorThe cytokinemacrophagemigration inhibitory factor plays a central role in inﬂammation, cell proliferation and
tumorigenesis. Moreover, macrophage migration inhibitory factor levels correlate with tumor aggressiveness
andmetastatic potential. Histone deacetylase inhibitors are potent antitumor agents recently introduced in the
clinic. Therefore, we hypothesized that macrophage migration inhibitory factor would represent a target of
histone deacetylase inhibitors. Conﬁrming our hypothesis, we report that histone deacetylase inhibitors of
various chemical classes strongly inhibited macrophage migration inhibitory factor expression in a broad
range of cell lines, in primary cells and in vivo. Nuclear run on, transient transfection with macrophage
migration inhibitory factor promoter reporter constructs and transduction with macrophage migration
inhibitory factor expressing adenovirus demonstrated that trichostatin A (a prototypical histone deacetylase
inhibitor) inhibited endogenous, but not episomal, MIF gene transcription. Interestingly, trichostatin A
induced a local and speciﬁc deacetylation of macrophage migration inhibitory factor promoter-associated H3
and H4 histones which did not affect chromatin accessibility but was associated with an impaired recruitment
of RNA polymerase II and Sp1 and CREB transcription factors required for basal MIF gene transcription.
Altogether, this study describes a new molecular mechanism by which histone deacetylase inhibitors inhibit
MIF gene expression, and suggests that macrophage migration inhibitory factor inhibition by histone
deacetylase inhibitors may contribute to the antitumorigenic effects of histone deacetylase inhibitors.
© 2009 Elsevier B.V. All rights reserved.1. Introduction
Macrophage migration inhibitory factor (MIF), one of the ﬁrst
cytokine activity identiﬁed [1,2], is a proinﬂammatory mediator that
plays a central role in the development of inﬂammation and innate
and adaptive immune responses [3]. MIF has been implicated in the
pathogenesis of acute and chronic infectious, inﬂammatory and
autoimmune diseases. In addition, recent studies strongly support
an important role for MIF in the control of cell growth and
tumorigenesis at multiple levels. MIF stimulates cell proliferation
through a sustained activation of the ERK1/2 MAPKs [4] and the
induction of cyclin D1 (CCND1) [5] and promotes cell survival by
inhibiting the p53 and retinoblastoma/E2F tumor suppressor path-
ways [6–8] and by activating the phosphoinositide-3-kinase (PI3K)/
Akt survival pathway [9]. Moreover, MIF promotes tumor-associated
neovascularization [10] and inhibits antitumor natural killer (NK) and+41 21 314 10 36.
ll rights reserved.cytotoxic T-lymphocyte (CTL) responses [11–14]. MIF also plays a role
in the control of the response to DNA damage [15] and regulates
tumor cell motility and invasion in a Rac1-dependent cell manner
[16]. Finally, human cancer tissues, such as prostate, breast, colon,
brain, skin and lung-derived tumors, have been shown to overexpress
MIF [17,18]. Altogether, an accumulating body of evidence indicates
that MIF have a crucial role in the development of inﬂammatory
diseases and neoplasia.
The structure of chromatin is inﬂuenced by covalent modiﬁcations
of amino-terminal tails of histones, particularly acetylation at lysine
residues [19–21]. Acetylation is regulated by the opposing actions of
histone acteyl transferases and histone deacetylases (HDACs).
Increased histone acetylation has been linked to gene overexpression
[22]. Transcription coactivators like p300/CBP and PCAF display
acetyltransferase activity whereas transcription co-repressor com-
plexes contain HDAC activity [23,24]. The current view is that histone
acetylation induces chromatin scaffolding to assume a more relaxed,
open structure increasing the accessibility of regulatory factors to
DNA and favoring active gene transcription. Yet, several observations
have challenged this traditional view. First, genome-wide expression
Table 1
Oligonucleotides used in this study.
Oligonucleotide 5′ -N 3′ sequence
Probe synthesis MIF S CACGCTCGCAGTCTCTC
MIF AS GAGGCTCAAAGAACAGC
p21 (CDKN1A) S GACACCACTGGAGGGTGACT
p21 (CDKN1A) AS GGATTAGGGCTTCCTCTTGG
Nuclear run-on MIF NRO S CCGGACAGGGTCTACATCAA
MIF NRO AS AATTCTCCCCACCAGAAGGT
ACTB NRO S TAAGGAGAAGCTGTGCTAGG
ACTB NRO AS TTGCTGATCCACATCTGCTG
EMSA Sp1p wt GCCTCGCGGGGGCGGGGCCTGGCG
Sp1p mt GCCTCGCGGGTAGAGGGCCTGGCG
CRE wt GCGGTGGCGTCACAAAAGGCGG
CRE mt GCCGGCGGTGGATACACAAAAGG
PCR MIF S GGTCTCCTGGTCCTTCTGC
MIF AS TGCACCGCGATGTACTGG
Ad-MIF S GCCAGAGGGGTTTCTGTC
Ad-MIF AS GTTCGTGCCGCTAAAAGTCA
HPRT S GAACGTCTTGCTCGAGATGTG
HPRT AS CCAGCAGGTCAGCAAAGAATT
ChIP and CHART MIF S3 TCCCAGCATCCTATCCTCTT
MIF S8 CGGTGACTTCCCCACTCG
MIF AS1 GGCACGTTGGTGTTGTTTACGAT
MIF AS3 TGGGGATGCGGCGGTGAACC
Base substitutions are underlined.
S: sense; AS: antisense; wt: wild-type; mt: mutant.
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expression of a small subset of cellular genes with similar proportions
of genes down-regulated and up-regulated [25–28]. Second, an
increasing number of non-histone proteins among which transcrip-
tion regulators have been shown to be modiﬁed by acetylation [21].
An abundant literature indicates that deregulation of acetylation
contributes to abnormal gene expression observed in many forms of
cancer. Therefore, HDACs are considered among the most promising
targets for intervention expected to reverse abnormal epigenetic
status in cancer cells [19–21]. In agreement, HDIs have shown
encouraging therapeutical results in preclinical studies [29] and the
broad spectrum HDI suberoylanilide hydroxamic acid (SAHA) has
been approved by the Food and Drug Administration for the treatment
of cutaneous T-cell lymphoma [30]. The powerful and speciﬁc
anticancer activities of HDIs result, to a great extent, from their
capacity to induce differentiation, growth arrest and/or apoptosis of
transformed cells. HDIs may also affect cancer development by
modifying tumor angiogenesis, metastasis and invasion and anti-
tumor immunity [19–21].
Considering that MIF is overexpressed in malignant cells and the
role played by MIF in tumorigenesis, we hypothesized that MIF could
be a target of HDIs. Here we report that HDIs strongly inhibit MIF
expression in various cell lines, primary cells and in vivo. Moreover,
we describe a new molecular mechanism by which TSA, a broad
spectrum HDI, inhibits MIF expression through a local and speciﬁc
deacetylation of histones associated with the proximal MIF promoter.
Altogether this study expands our comprehension of the mechanisms
by which HDIs inhibit gene expression and suggests that MIF is a
target of the antitumorigenic effects of HDIs.
2. Materials and methods
2.1. Cells, mice and reagents
Human HeLa cervix epithelial cells and HaCat keratinocytes and
mouse B16-10 melanoma were cultured in DMEM containing 4.5 g/
l glucose and 10% glutamax (Invitrogen). Human HL-60 promyelocy-
tic, U-937 promonocytic and THP-1 monocytic cell lines, KG1a
promyeloblasts and A549 airway epithelial cells were cultured in
RPMI 1640 medium containing 2 mM L-glutamine (Invitrogen). All
media contained 10% heat-inactivated fetal calf serum (Seromed).
Animal procedures were approved by the Ofﬁce Vétérinaire du
Canton de Vaud (authorizations no. 876.5 and 876.6) and performed
according to institution guidelines for animal experiments. Eight to
ten-week-old female BALB/c mice were purchased from Charles River
Laboratories (L'Arbresle, France). Mouse bone-marrow-derived
macrophages were obtained as previously described [31]. Mice (3
animals per group) were injected intraperitoneally with TSA (10 mg/
kg) or an equal volume of diluent every 24 h. After 2 days, blood was
collected. MIF in plasma (8 μl) was analyzed by Western blotting.
TSA and valproic acid (VPA) and mithramycin A were purchased
from Sigma-Aldrich and SAHA from ALEXIS Biochemicals. Recombi-
nant MIF and anti-human MIF antibodies isolated from the sera of
MIF-immunized New Zealand White rabbits were obtained as
previously described [32]. HeLa cells were transduced with the
empty control and MIF-expressing adenoviruses [16,33] at a multi-
plicity of infection of 100. The mediumwas replaced by fresh medium
1 h after viral infection, and incubation prolonged for 18 h before the
addition of TSA.
2.2. mRNA analysis
Total RNA was isolated using the RNeasy kit (Qiagen). MIF and
p21WAF1/CIP1 (p21 or cyclin-dependent kinase inhibitor 1A,
CDKN1A) mRNA steady state levels were assessed by Northern
blotting using PCR ampliﬁed DNA probes (primers are listed inTable 1). Quantiﬁcation of speciﬁc signals was performed using an
Instant Imager 2024 (Packard). Total RNA was reverse transcribed
using the ImProm-II Reverse Transcription System (Promega). MIF
and hypoxanthine phosphoribosyltransferase 1 (HPRT) mRNA
expression was analyzed by PCR. Quantitative PCR was performed
with a 7500 Fast Real-Time PCR System using the Power SYBR
Green PCR Master Mix (Applied Biosystems) as previously described
[34]. MIF mRNA expression was expressed relative to HPRT mRNA
expression in arbitrary units.
2.3. Western blot and co-immunoprecipitation analyses
Cells were lysed in Mammalian Protein Extraction Reagent
(Pierce). To detect histones, acid-soluble proteins were extracted as
previously described [35]. Cell-lysates and acid-insoluble proteins
were electrophoresed through polyacrylamide gels and transferred
onto nitrocellulose membranes. Membranes were incubated with
antihuman MIF, α-tubulin (T 5168, Sigma-Aldrich) and acetylated
histones H3 and H4 antibodies (06-755 and 05-858, Millipore),
washed and incubated with horse radish peroxidase (HRP)-conju-
gated secondary antibodies. Signals were revealed using the ECL
Western blotting analysis system (GE Healthcare).
For co-immunoprecipitation studies, total cell extracts were
obtained by incubating 107 HeLa cells in a lysis buffer containing
20 mM Tris–HCl pH 7.5, 150 mM NaCl, 1 mM EDTA, 1% Triton X-100,
2.5 mMNa4P2O7, 1 mM β-glycerophosphate, 4 mMNa3VO4 and 1 μg/
ml leupeptin. 200 μg of proteins were pre-absorbed with Protein G-
Sepharose ™ 4FF beads (Amersham). Supernatants were incubated
overnight at 4 °C with acetylated-Lysine antibody (9441S, Cell
Signaling Technology) and then with Protein G-Sepharose™ 4FF
beads for an additional 3 h. The beads were washed and heated 3 min
at 100 °C in electrophoresis sample buffer. Samples were analyzed by
SDS-PAGE and Western blotting using anti-Sp1 (sc-59x, Santa Cruz
Biotechnology) and HRP-conjugated immunopure rabbit antigoat IgG
antibody (31402, Pierce).
MIF protein decay was measured in HeLa cells pre-incubated for
1 h with or without TSA (1 μM) and then cultured with or without
cycloheximide (CHI, 10 μg/ml, Sigma-Aldrich). Protein extracts
were collected at intervals and analyzed by Western blotting as
described above.
1751J. Lugrin et al. / Biochimica et Biophysica Acta 1793 (2009) 1749–17582.4. Whole blood MIF secretion assay
Whole blood (200 μl) from healthy donors was diluted one in ﬁve
in RPMI mediumwith or without TSA and incubated 20 h at 37 °C in a
humidiﬁed incubator containing 5% CO2. Samples were centrifuged at
3000×g for 3 min. MIF levels in supernatants were measured by ELISA
as previously described [36].
2.5. Nuclear run-on
Nuclei isolation and in vitro transcription using biotin-16-UTP
(Roche) were performed as described [37]. RNA was isolated using
TRIzol® (Invitrogen), extracted with chloroform, precipitated with
isopropanol and resuspended in 50 μl sterile water. Total RNA (10 μl)
was conserved to monitor RNA input. Puriﬁcation of biotinylated RNA
transcripts was performed using the μMACS Streptavidin Kit accord-
ing to the manufacturer's instructions (Miltenyi Biotec). Input RNA
and biotinylated RNA were used for cDNA synthesis with random
hexamer primers. The level of MIF and β-actin cDNA in the
preparations was determined by PCR using speciﬁc oligonucleotides
(Table 1). The PCR conditions were as follows: 95 °C 15 min, followed
by 40 cycles consisting of 95 °C 30 s, 56 °C 30 s and 72 °C 1 min. PCR
products were analyzed by electrophoresis through agarose gels.
2.6. Transient transfection
The MIF promoter driven luciferase vectors have been described in
details [38]. HeLa cells (5×104) were platted in 24-well culture plates.
The following day, cells were transiently transfected using Fugene™
6 transfection reagent (Roche Diagnostics) and 100 ng of luciferase
reporter vectors [39]. Six hours later, transfected cells were exposed to
the drugs. After 18 h, cells were harvested. Luciferase activity was mea-
sured using the Dual-Luciferase™ Reporter Assay System (Promega).
2.7. Chromatin immunoprecipitation (ChIP)
Cells were treated with 1% formaldehyde for 30 min at 37 °C,
harvested, washed twice with cold PBS containing 1 mM PMSF and
0.9 μg/ml aprotinin, lysed in 50 mM Tris–HCl pH 8.0, 10 mM EDTA pH
8.0, 1% SDS, 1 mM PMSF and 0.9 μg/ml aprotinin (200 μl per 106 cells)
and sonicated using a Soniprep 150 (MSE) sonicator (5 × 30 s,
amplitude 14). Cleared lysates (200 μl) were diluted 10-fold in 1%
Triton X-100, 150mMNaCl, 20mMTris–HCl pH8.0, 2 mMEDTA pH 8.0,
1 mM PMSF and 0.9 μg/ml aprotinin. Twenty microliters were kept for
controls (input DNA). The rest of the preparation was incubated
overnight at 4 °C with 2.5 μg of control antibody (sc-2027, Santa Cruz
Biotechnology) or anti-acetylated histones H3 and H4 (06-599 and 06-
866, Upstate), anti-phosphorylated CREB (9198, Cell Signaling Technol-
ogy), anti-Sp1 (07-645, Upstate) and anti-RNApolymerase II (sc-9001x,
Santa Cruz Biotechnology) antibody. One hundredmicroliters of Protein
A Sepharose slurry (GE healthcare) were added to the lysates and the
mixtureswere incubated 2h at 4 °C. Beadswere extensivelywashed and
immune complexes were eluted in 450 μl 1% SDS and 100mMNaHCO3.
Input DNA and immunoprecipitated DNA were reverse-crosslinked,
puriﬁed by phenol:chloroform:isoamyl alcohol extraction, precipitated
with ethanol and resuspended in 50 μl of water. MIF promoter sequence
was detected by PCR using the S8 and AS1 primers (Table 1). The PCR
conditions were as for nuclear run-on. p21 promoter sequence was
detected as previously described [40]. Signals were quantiﬁed using an
Eagle eye video imaging system (Stratagene).
2.8. HDAC activity assay
HDAC activity in 50 μg of nuclear proteins was measured using the
HDAC assay kit (Millipore and BioVision) according to the manufac-
turer's recommendations.2.9. Chromatin accessibility by real-time PCR (CHART-PCR)
Cells were incubated 10 min on ice in 15 mM NaCl, 10 mM Tris pH
7.4, 1 mM EDTA, 0.1 mM EGTA, 50 mM KCl, 0.15 mM spermine,
0.5 mM spermidine, 0.2% NP40 and 5% sucrose. The suspension was
layered on a 10% sucrose cushion. After centrifugation, the nuclei were
recovered in 15 mM NaCl, 10 mM Tris pH 7.4, 50 mM KCl, 0.15 mM
spermine, 0.5 mM spermidine and 8.5% sucrose. Nuclei from 106 cells
were diluted in the recommended 1× restriction enzyme dilution
buffer and 1 U/μl of DraI or NotI. The reaction mixture was incubated
1 h at 37 °C. A non-digested control was included in the assay as well
as a puriﬁed DNA positive control. Genomic DNA was isolated using
the DNeasy Tissue kit (Qiagen), eluted in water, digested to
completion with XmaI and used in real-time PCR. Quantitative PCR
was performed with a Light Cycler (Roche) using the SYBR®-Green
PCR assay (Qiagen) and primer pairs S3/AS3 and S8/AS1 (Table 1)
overlapping the region of DNA targeted by restriction enzymes (Fig.
6). PCR conditions were as for nuclear run-on. Results of restriction
digest were normalized to the intact region and expressed as
percentage of non-digested DNA.
3. Results
3.1. HDIs down-regulates MIF expression
We used TSA, a broad spectrum prototypical HDI [19], to examine
whether HDIs affect MIF expression. Analyses of MIF mRNA steady
state levels in HeLa epithelial cells revealed that TSA decreased MIF
expression in a time- and dose-dependent manner (Fig. 1A and B). Of
note, other HDIs such as SAHA and valproic acid (VPA) inhibited MIF
mRNA expression in HeLa cells (Fig. 1C). TSA strongly reduced MIF
mRNA expression also in HaCat keratinocytes, HL-60, KG1a and U-937
leukemic cell lines, THP-1monocytic cells, A549 airway epithelial cells
and B16melanoma (Fig. 1D and data not shown). Conversely, TSAwas
shown to reactivate the expression of p21 (CDKN1A) in all cell lines
(Fig. 1A and D), indicating that the effect on MIF mRNA expression
was speciﬁc. In line with a strong inhibition of MIF mRNA expression,
TSA decreased intracellular MIF protein content in U-937, HaCat and
A549 cells in a time-dependent manner (Fig. 1E and data not shown).
TSA also strongly decreased MIF mRNA level in mouse bone-marrow-
derived macrophages (Fig. 1F) and MIF release in human whole blood
(Fig. 1G). Strengthening these in vitro observations, injection of TSA in
mice (10mg/kg intraperitoneally q24 h for 2 days) reducedMIF blood
levels two-fold (Fig. 1H). Overall, these data demonstrated that HDIs
inhibit MIF mRNA and protein expression in cells lines, primary cells
and in vivo.
3.2. TSA decreases MIF gene transcription
Nuclear run-on assays were used to determine whether TSA
inhibited MIF mRNA expression via a transcriptional mechanism.
Nuclei of U-937 cells cultured with or without TSA were isolated and
subjected to in vitro transcription using biotinylated UTP. Neo-
synthesized biotinylated messengers were isolated, reversed tran-
scribed and ampliﬁed by PCR using MIF and β-actin speciﬁc
oligonuleotides. The level of nascent MIF, but not β-actin, mRNA
was substantially reduced upon treatment with TSA (Fig. 2). These
data deﬁnitively indicated that TSA decreased MIF mRNA expression
by inhibiting the transcription of the MIF gene.
3.3. TSA targets endogenous MIF gene expression, but not ectopically
expressed MIF
To test whether TSA impaired MIF transcription by interfering
with MIF promoter activity, we ﬁrst thought to analyze the
transcriptional activity of MIF promoter (−858/+129, −308/+129,
Fig. 1. TSA down-regulates MIF expression. (A, B) Northern blot analysis of MIF and p21 (CDKN1A) mRNA expression in HeLa cells cultured for 18 hwith increasing concentrations of
TSA (A) or cultured for increasing time with 1 μM TSA (B). Uniform RNA loading was veriﬁed by ethidium bromide (EtBr) staining of 28S and 18S RNA. (C) MIF mRNA expression in
HeLa cells cultured 18 hwith TSA (1 μM), SAHA (1 μM) and valproic acid (VPA, 1 mM) analyzed by real time-PCR. Results are expressed as the ratio of MIF to HPRTmRNA levels. Data
are means±S.D. of triplicate samples from one experiment (pb0.005 for HDIs versus medium by two-tailed paired Student's t-test). (D) MIF and p21 mRNA expression in HaCat,
HeLa, HL60, KG1a and U-937 cells cultured for 18 hwith or without TSA (1 μM). (E)Western blot analysis of intracellular MIF in U-937 cells treated for 0, 2, 4 and 8 hwith TSA (1 μM).
Recombinant MIF (rMIF) was used as a standard. (F) MIF mRNA expression in mouse bone-marrow-derived macrophages cultured for 24 h with increasing concentrations of TSA.
Results are representative of at least two independent experiments (A-F). (G)Whole blood was incubated for 24 hwith TSA. MIF secretion was measured by ELISA. Data aremeans±
S.D. of triplicate samples from one experiment (p=0.02 and 0.005 for 4 and 100 nM TSA compared to medium by two-tailed paired Student's t-test). (H) BALB/c mice (n=3) were
injected with TSA (10 mg/kg i.p. q24h) or diluent (control) for 2 days. Blood was collected and a ﬁxed volume of plasma was used to analyze MIF expression by Western blotting.
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in HeLa cells. In agreement with high MIF mRNA expression in resting
HeLa cells, all but one construct (+44/+129) drove strong luciferase
activity (Fig. 3A). In contrast to expectations, TSA treatment strongly
increased luciferase activity driven by all MIF promoter reporterFig. 2. TSA inhibits MIF gene transcription. Nuclei were isolated from U-937 cells
treated for 8 h with or without TSA (1 μM) and subjected to in vitro transcription
analysis. MIF and β-actin mRNA levels in elongated and initiated transcripts (nascent)
and in total nuclear transcripts (input) were ampliﬁed by RT-PCR (see Materials and
methods). PCR products were analyzed by gel electrophoresis.constructs active at baseline. The proximal region of theMIF promoter
contains several DNA-binding sites among which are one c-Myb, two
Sp1 (Sp1p and Sp1d) and two cAMP response element (CREp and
CREd) sites (Fig. 3B). We previously reported that Sp1 and CREB bind
to the Sp1p and CREp sites to positively regulate MIF promoter activity
[38]. To analyze their involvement in TSA-induced transcriptional
activity of MIF promoter, the c-Myb, Sp1 and CRE sites were disrupted
in −157/+129 construct (Fig. 3B). Mutation of the cMyb and CRE
sites did not impact on TSA-induced MIF promoter activity. In
contrast, disruption of the Sp1p site and, to a lesser extent, of the
Sp1d site reduced MIF promoter induction by TSA. Furthermore,
mithramycin A, an antibiotic that interferes with Sp1 binding to DNA,
abrogated TSA-mediated increased activity of wild-type but not the
Sp1p mutant MIF promoter (Fig. 3C), conﬁrming that TSA increased
episomalMIF promoter activity through Sp1 DNA binding. Overall, the
effect of TSA on ectopically expressed MIF promoters did not
recapitulate the inhibitory effect observed on endogenous MIF gene,
Fig. 3. TSA increases episomal MIF promoter activity. (A–C) HeLa cells were transfected with an empty pGL3 vector, human MIF promoter deletion constructs (−858/+129,
−508/+129, −157/+129, −81/+129 and +44/+129) or the−157/+129 promoter construct with mutations (mt) in c-Myb, CREd, Sp1d, Sp1p and CREp DNA-binding sites. Of
note, the Sp1 and CRE DNA-binding sites that control constitutive transcriptional activity of the MIF gene are deleted from construct +44/+129. After 6 h, cells were treated with
or without TSA (1 μM) and mithramycin A (100 nM). Luciferase activity was determined 18 h latter (right panel). Data are means±S.D. of six determinations from one
experiment representative of two experiments. pb0.01 for medium versus TSA by two-tailed paired Student's t-test for −858/+129, −308/+129, −157/+129 and −81/+129
and for Sp1p mt versus the −157/+129.
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between episomal reporter constructs and endogenous chromosomal
genes.
To further demonstrate that TSA speciﬁcally inhibited endogenous
MIF expression, we transduced HeLa cells with an adenoviral vector
encoding MIF under the control of the CMV promoter. A PCR
discriminating between endogenous MIF mRNA and adenoviral-
derived MIF mRNA was used to evaluate the effect of TSA. As
previously observed (Fig. 1), TSA dose-dependently inhibited the
endogenousMIFmRNA steady state level (Fig. 4A). In contrast, TSA did
not affect adenoviral-derived MIF mRNA expression. In agreement
with these observations, TSA reducedMIF protein expression two-fold
in cells transduced with the control adenovirus, whereas it slightlyincreasedMIF protein level in cells transduced with the MIF-encoding
adenovirus (Fig. 4B). Altogether, these data argued in favor of a direct
inhibitory effect of TSA on endogenousMIF gene transcription.
3.4. TSA deacetylates the proximal MIF promoter
Because the association of trans-regulatory elements with pro-
moters occurs in the context of chromatin, we tested whether TSA
affected the acetylation status of histones H3 and H4 associated with
the proximal MIF promoter using chromatin immunoprecipitation
(ChIP) (Fig. 5A and B). Interestingly, TSA markedly reduced (two- to
three-fold) the level of acetylated histones H3 and H4 associated with
the MIF promoter in both U-937 and HeLa cells exposed to TSA. The
Fig. 4. TSA does not inhibit ectopically expressed MIF. HeLa cells were transduced with
an empty control (Ct) or MIF-expressing adenovirus (Ad) and treated 18 h later with
TSA (0.5 μM unless speciﬁed). RNA and proteins were recovered after 18 h. (A)
Endogenous MIF, adenovirus (Ad)-derived MIF and HPRTmRNA expression levels were
assessed by PCR. (B) MIF and tubulin expression was analyzed by Western blotting.
Recombinant MIF (rMIF) was processed in parallel to estimate MIF content in HeLa
cells. Results are representative of two independent experiments.
Fig. 5. TSA deacetylates the histones associated with the proximal region of the MIF
promoter. (A–C) U-937 and HeLa cells were treated for 10 hwith or without TSA (1 μM)
and analyzed by ChIP assay using anti-acetylated (ac) H3 and anti-acH4 antibodies.
Input and immunoprecipitated DNAwere subjected to PCR ampliﬁcation using primers
speciﬁc of the promoter region of theMIF (A, B) and p21 (C) genes. PCR were analyzed
by gel electrophoresis (A) and signals quantiﬁed by densitometry (B, C). Results are
representative of two independent experiments. (D) HDAC activity in nuclear extracts
from HeLa and U-937 cells treated for 10 h with increasing concentrations of TSA (0–
1 μM). Data are means±S.D. of duplicate samples from one experiment. (E) Histones
were extracted from U-937 cells treated for 10 h with or without TSA (1 μM) and
subjected to Western blot analysis using anti-acH3 and anti-acH4 antibodies. The gel
was colored with Ponceau Red to visualize total histones. Results are representative of
three independent experiments.
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increased the acetylation of histones H3 and H4 related to the p21
promoter (Fig. 5C). Moreover, as positive controls, we conﬁrmed that
TSA dose-dependently inhibited HDAC activity (Fig. 5D) at concen-
trations shown to inhibit MIF mRNA expression (Fig. 1) and raised
global acetylation of histones H3 and H4 (5.2- and 8.3-fold for
histones H3 and H4, Fig. 5E) in TSA-treated cells. Therefore,
deacetylation of the histones H3 and H4 associated with the MIF
promoter was an MIF-speciﬁc HDI effect.
To determine whether TSA-induced inhibition of MIF mRNA
expression and MIF promoter histone acetylation required newly
synthesized factors, U-937 cells were pretreated for 1 h with
cycloheximide before exposure to TSA. Cycloheximide given alone
gradually decreased MIF mRNA levels over time, indicating that MIF
mRNA expression required protein synthesis. TSA alone decreased
MIF mRNA levels similarly to CHI. The combination of cycloheximide
plus TSA increased MIF mRNA levels at an early time point (1.6-fold
increase after 2 h of treatment) but decreased MIF mRNA levels after
8 and 16 h as observed with cycloheximide or TSA (Fig. 6A).
Cycloheximide did not modify the acetylation of MIF promoter-
associated histones H3 and H4, whereas it counter-acted TSA-
mediated inhibition of histone acetylation (Fig. 6B). Thus, TSA
decreased MIF promoter histone acetylation and MIF mRNA expres-
sion through a molecular mechanism requiring de novo protein
synthesis.
3.5. TSA does not modify chromatin accessibility to the proximal
MIF promoter
The proximal region of the MIF promoter contains several DNA-
binding sites among which are one Sp1 (at −42 bp) and one cAMP
response element (CRE, at−20 bp) sites that we previously reported
to bind Sp1 and CREB to positively regulate MIF promoter activity
[38]. We therefore developed a chromatin accessibility by real-time
PCR (CHART-PCR) assay to test whether hypoacetylation of MIF-associated histones rendered the MIF promoter less accessible to Sp1
and CREB. Nuclei were isolated and incubated with DraI and NotI that
recognize sequences present in the distal and proximal regions of the
MIF promoter (at nucleotide −528 and +41, respectively, Fig. 7A).
Genomic DNA was subjected to real-time PCR ampliﬁcation using
primer pairs surrounding the DraI and NotI restriction sites. The
amount of material ampliﬁed was inversely proportional to the
Fig. 6. TSA decreases MIF promoter histone acetylation through amolecular mechanism
requiring de novo protein synthesis. Quantiﬁcation of MIF mRNA expression
determined by Northern blotting (A) and ChIP assay of acH3 and acH4 histones
associated with the proximal MIF promoter (B) in U-937 cells cultured for 1 h with or
without cycloheximide (CHI, 10 μg/ml) and then incubated for 10 h with or without
TSA (1 μM). Results are representative of two independent experiments.
Fig. 7. TSA does not impair the accessibility to the chromatin associated with the MIF
promoter. (A) Schematic representation of the MIF promoter showing MIF exon I (grey
box), the translational start site (upper arrow), the Sp1 and CRE DNA-binding sites that
regulate basal MIF promoter transcriptional activity, the DraI and NotI restriction sites
(nucleotide localization is relative to the transcriptional start site) and the relative
localization of S3/AS3 and S8/AS1 primer pairs used to amplify by real-time PCR the
DNA region surrounding the DraI and NotI sites. (B, C) Nuclei isolated from U-937 cells
(B) and HeLa cells (C) treated for 10 h with or without TSA (1 μM) were subjected to
digestion with DraI and NotI and analyzed by chromatin accessibility by real-time PCR.
A non-digested control as well as a puriﬁed DNA positive control was included in the
assays (data not shown). Data from restriction digests were normalized to those
obtained without digestion set at 1. Data are means±S.D. of three independent
determinations. Similar results were obtained using cells incubated for 4, 10 and 24 h
with TSA (data not shown).
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chromatin. In agreement with the localization of important transcrip-
tional regulatory elements in the vicinity of the MIF transcriptional
start site, the proximal region of the MIF promoter (examined by NotI
digestion) was highly accessible in both U-937 and HeLa cells.
Conversely, the distal region (examined by DraI digestion) was much
less accessible (Fig. 7B and C). When cells were incubated with TSA,
the accessibility to the proximal region of the MIF promoter slightly
increased in U-937 cells, whereas it was not modiﬁed in HeLa cells
(right panels in Fig. 7B and C). Finally, the accessibility to the distal
region of the MIF promoter was not affected by TSA (left panels in Fig.
7B and C). Thus, remodeling of chromatin accessibility by TSA was not
a major mechanism whereby TSA inhibited MIF gene transcription.
3.6. TSA decreases the recruitment of regulatory proteins to the proximal
MIF promoter
The hypoacetylation of the MIF proximal promoter induced by TSA
could potentially affect the binding of transcription regulatory factors
essential for basal MIF expression such as Sp1 and CREB [38] and
thereby prevent efﬁcient RNA polymerase II recruitment. To address
this question, we analyzed by ChIP the level of Sp1, CREB and RNA
polymerase II interacting with the proximal MIF promoter (Fig. 8A
and B). Whereas Sp1, CREB and RNA polymerase II were shown to be
bound to the MIF promoter in resting U-937 cells, TSA strongly
reduced their binding to DNA, which provided a molecular mecha-
nism by which TSA inhibitedMIF gene transcription. Of note, Western
blot analyses demonstrated that TSA did not reduce the quantity of
nuclear Sp1 and CREB (Fig. 8C and D). Moreover, co-immunoprecip-
itation analyses conﬁrmed that TSA increased Sp1 acetylation (Fig.
8D), which has been associated with Sp1 transcriptional activity [41].
Altogether, these results ruled out the possibility that TSA decreased
Sp1 and CREB binding to the endogenous MIF promoter by affecting
their expression level or Sp1 acetylation status.4. Discussion
We report that HDIs down-regulate the expression of the
proinﬂammatory and protumorigenic cytokine MIF through a new
molecular mechanism involving a local deacetylation of MIF promot-
er-associated histones which does not modify chromatin accessibility
but impairs the recruitment of the basal transcriptional machinery to
the proximal MIF promoter. Although the relative contribution of
speciﬁc HDACs in these process has not been determined, the
observation that chemically unrelated HDIs inhibited MIF expression
argues for an important contribution of HDAC in regulating MIF
expression.
Histone acetylation has been traditionally seen as a positive
marker for transcription. It is generally admitted that elevated histone
acetylation level induces a more open, transcriptionally more active
chromatin state. This notion is, however, hardly reconcilable with the
fact that HDIs, albeit strongly raising global histone acetylation,
induce transcriptional changes of only 2–10% of the transcriptome.
Interestingly, comparison of the transcriptome of different cancer cell
lines treated with HDIs has identiﬁed common subsets of genes being
Fig. 8. TSA decreases the binding of Sp1, CREB and RNA polymerase II to the proximal
region of theMIF promoter. HeLa cells were treated for 10 hwith or without TSA (1 μM)
and analyzed by ChIP assay using anti-Sp1, anti-phospho-CREB (pCREB) and anti-RNA
polymerase II (RNA Pol II) antibodies. (A) The immunoprecipitated DNA was subjected
to PCR ampliﬁcation using primers speciﬁc for the proximal region of the MIF promoter.
(B) Densitometric quantiﬁcation of the gels shown in panel A. (C–E) Western blot
analysis of Sp1 and phosphorylated CREB (pCREB) nuclear content (C, D) and co-
immunoprecipitation study of acetylated Sp1 expression (D) in HeLa cells treated with
TSA (1 μM in C, E) for the indicated time (C, E) or 10 h (D). Similar results were obtained
in two independent experiments.
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involved in cell cycle regulation, apoptosis, signaling and regulation of
transcription [25–28]. The basis for this selectivity remains largely
unknown and probably involves multiple components as HDIs modify
the acetylation status of an increasing list of non-histone substrates
including transcription factors and signal transduction mediators.
We found that MIF expression was strongly repressed by HDIs in a
broad range of cell lines, including myeloid cells, epithelial cells,
keratinocytes and melanoma. Considering that MIF is overexpressed
in multiple kinds of tumors and that MIF expression levels have been
associated with tumor aggressiveness and metastatic potential
[12,42,43], MIF may represent a common target of the anticancer
effects of HDIs.
While numerous studies have dissected the molecular mechan-
isms bywhich HDIs relieve gene expression, very little is known about
how these drugs repress gene expression, particularly constitutive
expression. Whereas TSA inhibited MIF gene transcription, it
vigorously activated ectopically expressed MIF promoters concomi-
tantly with an increased Sp1 acetylation. This effect was lost when the
proximal Sp1 DNA binding site wasmutated inMIF promoter reporter
constructs, which is in fact in agreementwith the observation that Sp1
acetylation increases its transcriptional activity [41]. Yet, of impor-
tance, these observations deﬁnitely illustrate the fundamental
differences that exist between episomal reporter constructs and
endogenous chromosomal genes and the risk of drawing conclusions
from the analysis of transfected reporter gene exposed to chromatin
remodeling agents [44].
In the context of HDAC inhibition, Sp1 regulatory elements, which
we previously demonstrated to regulate MIF promoter activity [38],
may have a dual role on ectopically expressed promoters. Indeed, Sp1
sites both increased (inhibitor of Cdk4, HMG-CoA synthase, CDKN1A
and EC-SOD) [45–48] and inhibited (BCL2 and TGFβ type II receptor)
[49,50] promoter activity upon TSA treatment. The dual role of Sp1sitesmight reﬂect differences in promoter speciﬁc sequences allowing
the recruitment of additional transcriptional co-regulators (activators
or repressors), acetylation-dependent modiﬁcations of Sp1 activity,
changes in chromatin architecture or even the cell type considered.
Considering that TSA strongly increased overall histone acetyla-
tion, it was unanticipated to detect a local deacetylation of histones
associated with the proximal MIF promoter in cells exposed to TSA.
MIF is one of the very rare examples of promoter deacetylation by
HDIs, with that of high-mobility-group A2 (HMGA2) in NIH-3T3 cells
[51] and of BCL2 in human lymphoma [49]. The local deacetylation of
these promoters, while in apparent contradiction with the pro-
acetylation properties of HDIs, is actually concordant with the fact
that HDIs repressed MIF, HMGA2 and BCL2 gene expression.
Genome-wide ChIP experiments (ChiP on Chip) combined with
transcriptome analyses will be required to have a comprehensive
view of the reciprocal inﬂuence of HDIs on histone acetylation and
gene expression.
Transcriptome analyses have revealed that inhibition of protein
synthesis by CHI prevents most of the effects of HDIs on gene
expression [52]. In line with this observation, CHI prevented histone
deacetylation by TSA. Co-treatment with TSA and CHI up-regulated
MIF mRNA expression early on, whereas TSA-mediated repression of
MIF mRNA expression required several hours. These data suggest that
inhibition of MIF mRNA synthesis by TSA is not a direct effect but
presumably belongs to a secondary response determined by de novo
synthesis of transcriptional repressors that remain to be identiﬁed. Of
note, we observed that TSA reduced MIF protein half-life from more
than 18 h in HeLa cells cultured with CHI with or without pre-
incubation for 1 h with TSA, to 4.5 h in cells cultured with TSA alone.
Therefore, TSA not only affectedMIF transcription, but also stimulated
MIF protein degradation through a process requiring protein
synthesis.
Considering that TSA reduced MIF promoter histone acetylation,
we speculated that this DNA region would be less accessible to Sp1
and CREB which positively regulate constitutive MIF gene expression
[38]. Whereas our ChIP experiments conﬁrmed that TSA reduced the
binding of Sp1, CREB and RNA polymerase II to the MIF promoter,
analysis of chromatin accessibility by real-time PCR clearly demon-
strated that the accessibility to the proximal region of the MIF
promoter was not affected by TSA. This unique situation challenges
the concept that hypoacetylated chromatin forms a compact structure
[24]. Since TSA did not impact on Sp1 and CREB expression levels,
further work will be required to test whether TSA displaces the
binding of Sp1 and CREB from the MIF promoter through a direct
modiﬁcation of these proteins affecting their DNA binding capacity or
through the recruitment of a transcriptional repressor competing
with, or disrupting, Sp1 and CREB DNA binding.
MIF promotes cell proliferation and survival through activation of
the PI3K/Akt survival pathway and through inhibition of the p53/
CDKN1A and retinoblastoma/E2F tumor suppressor pathways [6–8].
Conversely, HDIs have been reported to induce tumor cell apoptosis
by inhibiting Akt signaling which is constitutively activated in many
types of cancer [53–55]. Moreover, HDIs most invariably increase
tumor expression of CDKN1A in either a p53-dependent or a p53-
independent manner. Therefore, it is tempting to speculate that
inhibition of MIF expression by HDIs is a signiﬁcant contributor of the
pro-apoptotic effects of HDIs.
The inﬂammatory cells and mediators in the tumor microenvi-
ronment participate in neoplastic processes, orchestrating survival,
proliferation and migration of malignant cells, promoting angiogen-
esis and altering antitumor adaptive immune responses and response
to cancer therapy [56,57]. Besides its effect on cell proliferation and
survival, MIF has been reported to promote tumor-associated
angiogenesis [10] and to inhibit antitumor NK and CTL responses
[11–14]. Following these observations and considering the well-
established central role played by MIF in acute and chronic
1757J. Lugrin et al. / Biochimica et Biophysica Acta 1793 (2009) 1749–1758inﬂammatory responses [3], inhibition of MIF-mediated inﬂammation
by HDIs may represent an important facet by which HDIs interfere
with tumorigenesis.
Recent studies converge to attribute MIF an important role in
tumor development. Transplantation of neuroblastoma, ovarian
cancer and melanoma cell lines engineered to express reduced levels
of MIF resulted in delayed or reduced tumor establishment,
progression and metastasis and improved animal survival [14,58–
60]. Similarly, the development of chemically induced ﬁbrosarcoma
and muscle invasion of bladder cancer was impaired in MIF−/−
compared to wild-type mice [61,62]. Considering that TSA reduced
MIF blood levels in mice (Fig. 1H), it will be of interest to analyze
whether the anticancer activity of HDIs is associated with decreased
MIF expression in vivo.
In conclusion, we report that HDIs inhibit MIF gene expression
through a local deacetylation of MIF promoter-associated histones
that affects the recruitment of the basal transcription machinery. MIF
has a unique spectrum of biological activities, which positionsMIF as a
central mediator of inﬂammation and innate immunity and as an
important contributor to cell proliferation, malignant transformation
and angiogenesis. Bringing together the observations that MIF
expression levels correlate with tumor aggressiveness and metastatic
potential, that altered expression of HDACs contributes to tumor
development and that HDIs powerfully inhibit MIF expression, we
propose that MIF could represent a candidate for potential targeted or
adjunctive anticancer therapy.
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